サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1730949

メチルマロン酸血症（MMA）の世界市場レポート 2025年

Methylmalonic Acidemia (MMA) Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
メチルマロン酸血症（MMA）の世界市場レポート 2025年
出版日: 2025年05月16日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

メチルマロン酸血症（MMA）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.8％で125億米ドルに成長します。予測期間に予測される成長は、新生児スクリーニングプログラムの拡大、ヘルスケア専門家の意識の向上、遺伝子治療の進歩、希少疾患研究への投資の増加、専門的治療の利用可能性の向上などの要因によってもたらされます。この期間に予想される主な動向には、遺伝子編集技術の進歩、早期発見のための診断技術の強化、酵素補充療法の進歩、精密医療アプローチの採用、新生児遺伝子スクリーニングプログラムの実施拡大などがあります。

代謝性疾患とビタミン欠乏症の有病率の上昇は、メチルマロン酸血症（MMA）市場の成長を促進すると予想されます。代謝障害は、身体が特定の栄養素を処理したり、エネルギーを生産したり、細胞内の化学反応を調節したりするのに苦労する状態です。ビタミン欠乏症は、身体が適切に機能するのに十分な特定のビタミンが不足することで起こる。代謝異常やビタミン欠乏症の増加は、食生活の乱れ、座りがちな生活、ストレスレベルの高まりが主な原因となっています。加工食品、砂糖、不健康な脂肪が多く、必須栄養素が不足しがちな現代の食生活は、ビタミンやミネラルの欠乏を助長しています。こうした代謝異常やビタミン不足、特にビタミンB12の欠乏は、メチルマロニル-CoAの代謝を阻害し、メチルマロン酸の蓄積やMMAの悪化につながります。例えば、2024年11月、米国国立衛生研究所は、ビタミンB12欠乏症の有病率が4.6％から5.2％に上昇し、2023年第3四半期から第4四半期の間に507症例が追加されたと報告しました。その結果、代謝性疾患やビタミン欠乏症の発生率の増加がMMA市場の拡大に拍車をかけています。

MMA市場の主要企業は、MMAの遺伝的原因を標的とし、罹患者の有毒代謝産物の蓄積を抑えるために酵素機能を強化することによって治療成果を改善するために、mRNAベースの治療法などの革新的なソリューションの開発に注力しています。mRNAベースの治療法は、メッセンジャーRNAを使用して、遺伝性疾患を含む疾患の治療に役立つ特定のタンパク質を産生するように細胞に指示します。例えば、2024年6月、米国の製薬・バイオテクノロジー企業であるModerna, Inc.は、FDAからmRNA-3705をSTART試験プログラムに含める承認を取得しました。この治療薬は、プロピオン酸血症に対するmRNA-3927プログラムでも採用されている、Moderna独自の脂質ナノ粒子（LNP）システムを使用しています。FDAはmRNA-3705に希少疾病用医薬品、ファスト・トラック、希少小児疾患の指定を与え、開発と臨床の進捗を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界のメチルマロン酸血症（MMA） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界のメチルマロン酸血症（MMA）市場：成長率分析
  • 世界のメチルマロン酸血症（MMA）市場の実績：規模と成長、2019年～2024年
  • 世界のメチルマロン酸血症（MMA）市場の予測：規模と成長、2024年～2029年、2034年
  • 世界のメチルマロン酸血症（MMA）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界のメチルマロン酸血症（MMA）市場：適応症別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • アシドーシス
  • ケトーシス
  • 高アンモニア血症
  • 低血糖
  • 高血糖
  • 好中球減少症
  • その他の適応症
  • 世界のメチルマロン酸血症（MMA）市場：障害タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • ホモシスチン尿症
  • 単離メチルマロン酸尿症
  • メチルマロン酸尿症の複合
  • 世界のメチルマロン酸血症（MMA）市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 病院
  • 薬局
  • クリニック
  • その他の流通チャネル
  • 世界のメチルマロン酸血症（MMA）市場、アシドーシスの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 代謝性アシドーシス
  • 乳酸アシドーシス
  • 世界のメチルマロン酸血症（MMA）市場、ケトーシスのタイプ別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 飢餓誘発性ケトーシス
  • 糖尿病性ケトアシドーシス
  • 世界のメチルマロン酸血症（MMA）市場、高アンモニア血症の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 急性高アンモニア血症
  • 慢性高アンモニア血症
  • 世界のメチルマロン酸血症（MMA）市場、低血糖の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 空腹時低血糖
  • 反応性低血糖
  • 世界のメチルマロン酸血症（MMA）市場、好中球減少症の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 重度の好中球減少症
  • 周期性好中球減少症
  • 世界のメチルマロン酸血症（MMA）市場、その他の適応症のサブセグメンテーション（タイプ別）、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 発育不全
  • 発達遅延
  • 神経症状
  • 腎機能障害

第7章 地域別・国別分析

  • 世界のメチルマロン酸血症（MMA）市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 世界のメチルマロン酸血症（MMA）市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • メチルマロン酸血症（MMA）市場：競合情勢
  • メチルマロン酸血症（MMA）市場：企業プロファイル
    • Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Lonza Group Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Alexion Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
    • PTC Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Ironwood Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Wockhardt Limited
  • Spectrum Chemical Manufacturing Corp.
  • Asklepios BioPharmaceutical Inc.（AskBio）
  • Selecta Biosciences Inc.
  • BTG International Inc.
  • BridgeBio Pharma Inc.
  • VectivBio Holding AG
  • Supriya Lifescience Ltd.
  • Recordati Rare Diseases Inc.
  • Agios Pharmaceuticals Inc.
  • AdvaCare Pharma USA LLC
  • LogicBio Therapeutics Inc.
  • HemoShear Therapeutics LLC
  • Manus Aktteva Biopharma LLP
  • Deccan Nutraceuticals Pvt. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • メチルマロン酸血症（MMA）市場2029年：新たな機会を提供する国
  • メチルマロン酸血症（MMA）市場2029年：新たな機会を提供するセグメント
  • メチルマロン酸血症（MMA）市場2029年：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34621

Methylmalonic acidemia (MMA) is a rare inherited metabolic disorder in which the body is unable to effectively break down certain proteins and fats due to a deficiency in the enzyme methylmalonyl-CoA mutase or a related coenzyme, vitamin B12. The severity of MMA symptoms can vary, but they often include vomiting, lethargy, poor feeding, developmental delay, seizures, and failure to thrive.

The primary indications for methylmalonic acidemia (MMA) include acidosis, ketosis, hyperammonemia, hypoglycemia, hyperglycemia, neutropenia, and other related conditions. Acidosis refers to an excess of acid in the blood, resulting in a lower-than-normal pH level. There are various types of disorders associated with MMA, such as homocystinuria, isolated methylmalonic acidurias, and combined methylmalonic aciduria. These treatments and interventions are available through different distribution channels, including hospitals, pharmacies, clinics, and other outlets.

The methylmalonic acidemia (MMA) market research report is one of a series of new reports from The Business Research Company that provides methylmalonic acidemia (MMA) market statistics, including the methylmalonic acidemia (MMA) industry global market size, regional shares, competitors with the methylmalonic acidemia (MMA) market share, detailed methylmalonic acidemia (MMA) market segments, market trends, and opportunities, and any further data you may need to thrive in the methylmalonic acidemia (MMA) industry. This methylmalonic acidemia (MMA) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The methylmalonic acidemia (MMA) market size has grown strongly in recent years. It will grow from $9.39 billion in 2024 to $9.97 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth observed in the historical period can be attributed to factors such as the rising incidence of metabolic disorders and vitamin deficiencies, increased healthcare spending, greater health consciousness, a higher prevalence of genetic disorders, and growing demand from various end-user industries.

The methylmalonic acidemia (MMA) market size is expected to see strong growth in the next few years. It will grow to $12.50 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth projected for the forecast period is driven by factors such as the expansion of newborn screening programs, increased awareness among healthcare professionals, advancements in gene therapy, growing investments in rare disease research, and improved availability of specialized treatments. Key trends expected during this period include advancements in gene editing technologies, enhanced diagnostic techniques for early detection, progress in enzyme replacement therapies, the adoption of precision medicine approaches, and the growing implementation of newborn genetic screening programs.

The rising prevalence of metabolic disorders and vitamin deficiencies is expected to drive the growth of the methylmalonic acidemia (MMA) market. Metabolic disorders are conditions where the body struggles to process certain nutrients, produce energy, or regulate chemical reactions within cells. Vitamin deficiencies occur when the body lacks enough specific vitamins to function properly. The increase in metabolic disorders and vitamin deficiencies is largely attributed to poor diets, sedentary lifestyles, and heightened stress levels. Modern diets, which are often rich in processed foods, sugars, and unhealthy fats while lacking essential nutrients, contribute to deficiencies in vitamins and minerals. These metabolic disorders and vitamin deficiencies, especially vitamin B12 deficiency, disrupt methylmalonyl-CoA metabolism, leading to the buildup of methylmalonic acid and worsening MMA. For example, in November 2024, the National Institutes of Health reported that the prevalence of vitamin B12 deficiency rose from 4.6% to 5.2%, adding 507 cases between the third and fourth quarters of 2023. As a result, the growing incidence of metabolic disorders and vitamin deficiencies is fueling the expansion of the MMA market.

Leading companies in the MMA market are focusing on developing innovative solutions, such as mRNA-based therapies, to improve treatment outcomes by targeting the genetic causes of MMA and enhancing enzyme function to reduce the accumulation of toxic metabolites in affected individuals. mRNA-based therapies use messenger RNA to instruct cells to produce specific proteins that help treat diseases, including genetic disorders. For example, in June 2024, Moderna, Inc., a US-based pharmaceutical and biotechnology company, received FDA approval to include mRNA-3705 in the START pilot program, a significant advancement for rare disease treatments. mRNA-3705 is an investigational therapy for MMA caused by MUT deficiency, designed to restore the missing enzyme using mRNA technology. The therapy uses Moderna's proprietary lipid nanoparticle (LNP) system, also employed in the mRNA-3927 program for propionic acidemia. The FDA has granted mRNA-3705 orphan drug, fast track, and rare pediatric disease designations, expediting its development and clinical progress.

In October 2022, Alexion Pharmaceuticals, a US-based biopharmaceutical company, acquired LogicBio Therapeutics for approximately $68.2 million. This acquisition aims to accelerate Alexion's growth in genomic medicines by utilizing unique technology, a talented rare disease research team, and expertise in preclinical development. LogicBio Therapeutics, Inc. is a US-based biotechnology company specializing in gene-editing and gene therapy solutions for rare genetic diseases, including MMA.

Major players in the methylmalonic acidemia (mma) market are Moderna Inc., Lonza Group Ltd., Alexion Pharmaceuticals Inc., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Wockhardt Limited, Spectrum Chemical Manufacturing Corp., Asklepios BioPharmaceutical Inc. (AskBio), Selecta Biosciences Inc., BTG International Inc., BridgeBio Pharma Inc., VectivBio Holding AG, Supriya Lifescience Ltd., Recordati Rare Diseases Inc., Agios Pharmaceuticals Inc., AdvaCare Pharma USA LLC, LogicBio Therapeutics Inc., HemoShear Therapeutics LLC, Manus Aktteva Biopharma LLP, Deccan Nutraceuticals Pvt. Ltd.

North America was the largest region in the methylmalonic acidemia (MMA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in methylmalonic acidemia (MMA) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the methylmalonic acidemia (MMA) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The methylmalonic acidemia (MMA) market consists of revenues earned by entities by providing services such as medical management, dietary support, and vitamin and medication therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The methylmalonic acidemia market includes sales of hydroxocobalamin, vitamin B12 tablets, other pharmaceutical and therapeutic products, dietary products, and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Methylmalonic Acidemia (MMA) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on methylmalonic acidemia (mma) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for methylmalonic acidemia (mma) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The methylmalonic acidemia (mma) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Indication: Acidosis; Ketosis; Hyperammonemia; Hypoglycaemia; Hyperglycaemia; Neutropenia; Other Indications
  • 2) By Disorder Type: Homocystinuria; Isolated Methylmalonic Acidurias; Combined methylmalonic Aciduria
  • 3) By Distribution Channel: Hospitals; Pharmacies; Clinics; Other Distribution Channels
  • Subsegments:
  • 1) By Acidosis: Metabolic Acidosis; Lactic Acidosis
  • 2) By Ketosis: Starvation-Induced Ketosis; Diabetic Ketoacidosis
  • 3) By Hyperammonemia: Acute Hyperammonemia; Chronic Hyperammonemia
  • 4) By Hypoglycemia: Fasting Hypoglycemia; Reactive Hypoglycemi
  • 5) By Hyperglycemia: Transient Hyperglycemia; Persistent Hyperglycemia
  • 6) By Neutropenia: Severe Neutropenia; Cyclic Neutropenia
  • 7) By Other Indications: Failure to Thrive; Developmental Delays; Neurological Symptoms; Renal Dysfunction
  • Companies Mentioned: Moderna Inc.; Lonza Group Ltd.; Alexion Pharmaceuticals Inc.; PTC Therapeutics Inc.; Ironwood Pharmaceuticals Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Methylmalonic Acidemia (MMA) Market Characteristics

3. Methylmalonic Acidemia (MMA) Market Trends And Strategies

4. Methylmalonic Acidemia (MMA) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Methylmalonic Acidemia (MMA) Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Methylmalonic Acidemia (MMA) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Methylmalonic Acidemia (MMA) Market Growth Rate Analysis
  • 5.4. Global Methylmalonic Acidemia (MMA) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Methylmalonic Acidemia (MMA) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Methylmalonic Acidemia (MMA) Total Addressable Market (TAM)

6. Methylmalonic Acidemia (MMA) Market Segmentation

  • 6.1. Global Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Acidosis
  • Ketosis
  • Hyperammonemia
  • Hypoglycaemia
  • Hyperglycaemia
  • Neutropenia
  • Other Indications
  • 6.2. Global Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Homocystinuria
  • Isolated Methylmalonic Acidurias
  • Combined methylmalonic Aciduria
  • 6.3. Global Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Pharmacies
  • Clinics
  • Other Distribution Channels
  • 6.4. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Acidosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Metabolic Acidosis
  • Lactic Acidosis
  • 6.5. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Ketosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Starvation-Induced Ketosis
  • Diabetic Ketoacidosis
  • 6.6. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Hyperammonemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Acute Hyperammonemia
  • Chronic Hyperammonemia
  • 6.7. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Hypoglycemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Fasting Hypoglycemia
  • Reactive Hypoglycemi
  • 6.8. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Neutropenia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Severe Neutropenia
  • Cyclic Neutropenia
  • 6.9. Global Methylmalonic Acidemia (MMA) Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Failure to Thrive
  • Developmental Delays
  • Neurological Symptoms
  • Renal Dysfunction

7. Methylmalonic Acidemia (MMA) Market Regional And Country Analysis

  • 7.1. Global Methylmalonic Acidemia (MMA) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Methylmalonic Acidemia (MMA) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Methylmalonic Acidemia (MMA) Market

  • 8.1. Asia-Pacific Methylmalonic Acidemia (MMA) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Methylmalonic Acidemia (MMA) Market

  • 9.1. China Methylmalonic Acidemia (MMA) Market Overview
  • 9.2. China Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Methylmalonic Acidemia (MMA) Market

  • 10.1. India Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Methylmalonic Acidemia (MMA) Market

  • 11.1. Japan Methylmalonic Acidemia (MMA) Market Overview
  • 11.2. Japan Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Methylmalonic Acidemia (MMA) Market

  • 12.1. Australia Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Methylmalonic Acidemia (MMA) Market

  • 13.1. Indonesia Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Methylmalonic Acidemia (MMA) Market

  • 14.1. South Korea Methylmalonic Acidemia (MMA) Market Overview
  • 14.2. South Korea Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Methylmalonic Acidemia (MMA) Market

  • 15.1. Western Europe Methylmalonic Acidemia (MMA) Market Overview
  • 15.2. Western Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Methylmalonic Acidemia (MMA) Market

  • 16.1. UK Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Methylmalonic Acidemia (MMA) Market

  • 17.1. Germany Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Methylmalonic Acidemia (MMA) Market

  • 18.1. France Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Methylmalonic Acidemia (MMA) Market

  • 19.1. Italy Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Methylmalonic Acidemia (MMA) Market

  • 20.1. Spain Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Methylmalonic Acidemia (MMA) Market

  • 21.1. Eastern Europe Methylmalonic Acidemia (MMA) Market Overview
  • 21.2. Eastern Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Methylmalonic Acidemia (MMA) Market

  • 22.1. Russia Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Methylmalonic Acidemia (MMA) Market

  • 23.1. North America Methylmalonic Acidemia (MMA) Market Overview
  • 23.2. North America Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Methylmalonic Acidemia (MMA) Market

  • 24.1. USA Methylmalonic Acidemia (MMA) Market Overview
  • 24.2. USA Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Methylmalonic Acidemia (MMA) Market

  • 25.1. Canada Methylmalonic Acidemia (MMA) Market Overview
  • 25.2. Canada Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Methylmalonic Acidemia (MMA) Market

  • 26.1. South America Methylmalonic Acidemia (MMA) Market Overview
  • 26.2. South America Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Methylmalonic Acidemia (MMA) Market

  • 27.1. Brazil Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Methylmalonic Acidemia (MMA) Market

  • 28.1. Middle East Methylmalonic Acidemia (MMA) Market Overview
  • 28.2. Middle East Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Methylmalonic Acidemia (MMA) Market

  • 29.1. Africa Methylmalonic Acidemia (MMA) Market Overview
  • 29.2. Africa Methylmalonic Acidemia (MMA) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Methylmalonic Acidemia (MMA) Market, Segmentation By Disorder Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Methylmalonic Acidemia (MMA) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Methylmalonic Acidemia (MMA) Market Competitive Landscape And Company Profiles

  • 30.1. Methylmalonic Acidemia (MMA) Market Competitive Landscape
  • 30.2. Methylmalonic Acidemia (MMA) Market Company Profiles
    • 30.2.1. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Lonza Group Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Alexion Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. PTC Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Ironwood Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Methylmalonic Acidemia (MMA) Market Other Major And Innovative Companies

  • 31.1. Wockhardt Limited
  • 31.2. Spectrum Chemical Manufacturing Corp.
  • 31.3. Asklepios BioPharmaceutical Inc. (AskBio)
  • 31.4. Selecta Biosciences Inc.
  • 31.5. BTG International Inc.
  • 31.6. BridgeBio Pharma Inc.
  • 31.7. VectivBio Holding AG
  • 31.8. Supriya Lifescience Ltd.
  • 31.9. Recordati Rare Diseases Inc.
  • 31.10. Agios Pharmaceuticals Inc.
  • 31.11. AdvaCare Pharma USA LLC
  • 31.12. LogicBio Therapeutics Inc.
  • 31.13. HemoShear Therapeutics LLC
  • 31.14. Manus Aktteva Biopharma LLP
  • 31.15. Deccan Nutraceuticals Pvt. Ltd.

32. Global Methylmalonic Acidemia (MMA) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Methylmalonic Acidemia (MMA) Market

34. Recent Developments In The Methylmalonic Acidemia (MMA) Market

35. Methylmalonic Acidemia (MMA) Market High Potential Countries, Segments and Strategies

  • 35.1 Methylmalonic Acidemia (MMA) Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Methylmalonic Acidemia (MMA) Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Methylmalonic Acidemia (MMA) Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer